



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TESAMORELIN

Generic	Brand	HICL	GCN	Exception/Other
TESAMORELIN	EGRIFTA	37268		

GUIDELINES FOR USE

1. Is the requested drug being used for the reduction of excess abdominal fat in an HIV-infected patient who has lipodystrophy syndrome?

If yes, continue to #2.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the patient currently receiving treatment with a protease inhibitor (PI), PI combination (i.e., saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI), or an NRTI combination (i.e., zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)?

If yes, **approve for 3 months by HICL with a quantity limit of #60 vials per month.**

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

DENIAL TEXT: The guideline named **TESAMORELIN (Egrifta)** requires that the drug is being used for the reduction of excess abdominal fat in HIV-infected patients who have lipodystrophy syndrome. In addition, patients must be receiving treatment with a protease inhibitor (PI), PI combination (i.e., saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI), or an NRTI combination (i.e., zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir).

RATIONALE

Ensure that tesamorelin is used solely for its FDA approved indication.

FDA APPROVED INDICATION

Tesamorelin is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

REFERENCES

- EMD Serono, Inc. Egrifta package insert. Rockland, MA. November 2010.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TESAMORELIN

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/17

Created: 02/11

Client Approval: 02/17

P&T Approval: 02/11